The oncologist · 2026
Home-based supervised exercise on metastatic cancer patients receiving oral targeted therapy: the AFSOS-Unicancer QUALIOR randomized phase 2 study.
СтатьяКлиническое исследование II фазыРандомизированное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Joly Florence, Lefeuvre-Plesse Claudia, Charton Emilie, Helissey Carole, Priou Franck, Stefani Laetitia, Simmet Victor, Bonnet Elise, Meneveau Nathalie, Houede Nathalie, Salas Sébastien, Bourbouloux Emmanuelle, Nenan Soazig, Rieger Isabelle, Descotes Jean-Marc, Anota Amélie
Аннотация
BACKGROUND: QUALIOR-phase 2 multicenter trial explored the feasibility of a home-based supervised physical exercise program (SPEP) in metastatic cancer patients receiving oral targeted therapies.
METHODS: Patients with metastatic cancers receiving oral targeted therapies were randomized (2:1) to a 3-month home-based SPEP (with a coach at home) or recommended adapted physical exercises (booklet). Primary endpoint was feasibility defined as the rate of patients who performed at least 50% of the theoretically planned sessions in the SPEP arm. Main secondary endpoints were fatigue and pain evaluated by visual analogue scales (VAS) during the program.
RESULTS: Among 112 patients, 74 and 38 were included in the SPEP and control arms, respectively. Median age was 59 (range: 31-83) years and the majority of patients were women. Main primary tumor location was breast (57%) and kidney (16%). Thirty-three (30%) patients were treated with anti-angiogenic tyrosine kinase inhibitors, and 53 (47%) received epidermal growth factor receptor or cell cycle inhibitors. Forty-five (61%) patients performed at least 50% of the SPEP. Median fatigue decreased from 4 to 3 (range: 0-10) after 3 months in the SPEP group with maintain of pain control. The percentage of patients with high level VAS of fatigue at 3 months was lower in SPEP arm than in the control arm (27% vs. 62%, P = .004).
CONCLUSIONS: QUALIOR showed that SPEP with a coach at home was feasible in patients with metastatic cancers treated with oral targeted therapies. This program could mitigate the fatigue induced by oral targeted therapies.
METHODS: Patients with metastatic cancers receiving oral targeted therapies were randomized (2:1) to a 3-month home-based SPEP (with a coach at home) or recommended adapted physical exercises (booklet). Primary endpoint was feasibility defined as the rate of patients who performed at least 50% of the theoretically planned sessions in the SPEP arm. Main secondary endpoints were fatigue and pain evaluated by visual analogue scales (VAS) during the program.
RESULTS: Among 112 patients, 74 and 38 were included in the SPEP and control arms, respectively. Median age was 59 (range: 31-83) years and the majority of patients were women. Main primary tumor location was breast (57%) and kidney (16%). Thirty-three (30%) patients were treated with anti-angiogenic tyrosine kinase inhibitors, and 53 (47%) received epidermal growth factor receptor or cell cycle inhibitors. Forty-five (61%) patients performed at least 50% of the SPEP. Median fatigue decreased from 4 to 3 (range: 0-10) after 3 months in the SPEP group with maintain of pain control. The percentage of patients with high level VAS of fatigue at 3 months was lower in SPEP arm than in the control arm (27% vs. 62%, P = .004).
CONCLUSIONS: QUALIOR showed that SPEP with a coach at home was feasible in patients with metastatic cancers treated with oral targeted therapies. This program could mitigate the fatigue induced by oral targeted therapies.